Search

Displaying results 1121 - 1130 of 8517 in total
  1. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. … It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

  2. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  3. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377]. … Panthenol exists as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol).

  4. Drug

    Thymol

    go.drugbank.com/drugs/DB02513
    ApprovedInvestigational

    It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)

  5. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.

  6. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  7. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … [A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.

  8. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Cocoa butter is included in chocolate and other food products, and can also be found in over-the-counter skin products such as lotions, creams, and bars intended to maintain skin softness. … While cocoa butter has skin moisturizing properties, it was not shown to reduce the likelihood of developing of striae gravidarum, or stretch marks, in a double-blind, randomized clinical trial of women

  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

  10. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]